New drug cocktail shows promise for Tough-to-Treat blood cancers
NCT ID NCT04447027
First seen Jan 31, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had come back or stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at whether the treatment shrank tumors. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.